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In the last several years a number of new nonglycoside
positive inotropic agents have been developed for the treat-
ment of patients with congestive heart failure
. These new
drugs fall into two major categories: the beta-adrenergic
agonists and the phosphodiesterase inhibitors (1) . Both
classes of agents produce marked hemodynamic improve-
ment and appear in clinical practice to exert a substantially
greater positive inotropic action than does digitalis
. The
intravenously administered beta-adrenergic agonists, dopa-
mine and dobutamine, are now widely used in the short-term
management of patients with heart failure. In 1978, the initial
hemodynamic effects of intravenous amrinone were reported
and, subsequently, this agent was approved by the Food and
Drug Administration for the short-term management of
severe heart failure
. Several new second-generation phos-
phodiesterase inhibitors (such as milrinone, enoximone and
piroximone) are available orally on an investigational basis .
Theoretical concerns. The development of potent positive
inotropic agents has led to concerns that sustained inotropic
stimulation may produce an adverse effect on the survival of
patients with congestive heart failure . This concern, initially
articulated by Katz (2,3) and subsequently by Packer et al .
(4,5), was based on three theoretical fears . First, positive
inotropic agents would adversely affect myocardial energet-
ics, thereby hastening the rate of myocardial deterioration .
Second, agents that increase myocardial cyclic adenosine
monophosphate (AMP) or calcium would provoke complex
ventricular arrhythmias, thereby leading to an increase in the
incidence of sudden cardiac death
. Third, agents that in-
crease myocardial calcium would impair myocardial-dias-
tolic relaxation, thereby leading to an increase in diastolic
wall stress and cardiac filling pressures .
It is important that these theoretical issues be addressed
by prospective, placebo-controlled, double-blind trials . It is
particularly imperative that we avoid conclusions based on
uncontrolled observations. Although the results of uncon-
trolled studies may appear to support certain theoretical
arguments, other explanations for observed phenomena are
usually possible and cannot be excluded in the absence of
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controlled data . This important point was emphasized by
Packer and Leier (5), who noted, "Most of the patients
treated with phosphodiesterase inhibitors were severely ill,
were deteriorating clinically before therapy and had previ-
ously failed vasodilator therapy, often including captopril ."
These authors concluded that "it is possible that unmea-
sured variables were present before therapy in patients
treated with positive inotropic agents that contributed im-
portantly both to the decision to refer such patients for
therapy and to their extremely poor long-term prognosis
."
Controlled trials are now available, which provide informa-
tion regarding the effects of long-term positive agents on the
clinical status, functional capacity and survival of patients
with chronic heart failure .
Effect of beta-adrenergic agonists on survival in heart
failure
. Attempts to use orally active beta-adrenergic all
ists for the treatment of heart failure have not been success-
ful, in large part because tolerance develops to the hemody-
namic effects of such agents during long-term therapy
(1).
Accordingly, patients fail to show persistent hemodynamic
and clinical responses to pirbnterol and prenalterol after
these orally active betaadrenergic agonists have been ad-
ministered for several days (6,7)
. This hemodynamic atten-
uation appears to be related to a down-regulation of beta-
adrenergic receptors (7) because any prolonged exposure to
catecholamines (both experimentally and clinically) results
in desensitization of the beta-adrenergic pathway. For ex-
ample, 5 days of treatment with a beta-adrenergic agonist in
the rat results in total loss of the myocardial inotropic
responses to pirbuterol and prenalterol, two orally active
beta-adrenergic agonists (8)
.
Because intermittent exposure to cateeholamines may
circumvent the development of tolerance, intermittent ther-
apy' with beta-agonists could conceivably avoid the limita-
tions
of
continuous treatment . When preliminary data (9,10)
suggested that intermittent infusions of dobutamine could
favorably affect the clinical stator of patients with chronic
heart failure, this therapeutic approach was prospectively
evaluated in a controlled trial (11,12)
. Sixty patients with
severe chronic heart failure (ivew York Heart Association
functional classes III and IV) were randomly assigned to
placebo (n = 29) or dobutamine In = 31) . After an initial
in-hospital evaluation of intravenous dobutamine therapy,
patients were discharged home for 24 weeks, where they
received an infusion of dobutamine (mean dose 8 .1 pgikg per
min) or placebo for 48 h each week by way of an ambulatory,
battery-driven infusion pump; 5 days elapsed bt'ween each
infusion of the drag. Exercise capacity increased more in
dobutamine-treated patients than in patients treated with
placebo (dobutamine +91%; placebo +13% ; p < 0.05)
(11,12) . In addition, clinical deterioration occurred less
frequently in the dobutamine-treated group ; seven patients
were crossed over from placebo to dobutamine because of
worsening symptoms of heart failure, whereas only one
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patient was crossed over from dobutamine to placebo be-
cause of clinical instability (p < 0 .03) .
Of the 37 patients who received dobutamine in this trial
(11,12), 15 died (10 suddenly, 4 of progressive heart failure
and I of sepsis) ; of these 15 patients, T
died during the
infusion of the drug. Of the 23 patients who were being
treated with placebo during their last visit, 5 died (4 suddenly
and I of progressive heart failure) ; of these 5 patients, none
died during the infusion of placebo . Although the diffeance
in mortality between the two groups was not statistically
significant, there was a trend toward a higher mortality in
patients treated with dobutamine by both an "intention to
treat" In = 0 .147) and by an "actual treatment" analysis (p
= 0.06). Although the latter analysis suggested that dobuta-
mine was associated with an adverse effect on the survival of
patients in this study, an "actual treatment" analysis maybe
misleading because patients whose clinical state was deteri-
orating were frequently crossed over from placebo to dobu-
tamine . Hence, it is possible that the deaths in this study
were related to the therapy that patients were taking when
their clinical status began to deteriorate rather than the
therapy they were taking when they died. Nonetheless, the
findings of this study show a trend toward a nigher mortality
in patients with chronic heart failure receiving long-term
treatment with beta-agonists, a finding that warrants careful
consideration.
Effects or dobutamine on sudden death and progression of
heartfadurt . The results of the dobutamine trial permit us to
address specific concerns about the long-term effects of
positive inotropic agents in chronic congestive heart failure .
Does positive inotropic stimulation lead to a higher
incidence of redden death? Apparently not, because the
incidence of sudden death in patients treated with debuts-
mine (67%) was not higher than that in patients treated with
placebo (80%). Does positive inotropic stimulation lead to an
accelerated deterioration of cardiac function? Apparently
not, because seven of the eight patients whose clinical state
deteriorated during the study were being treated with pla-
cebo, and exercise capacity improved only in the dobuta-
mine-treated patients . Although myocardial function was not
directly meas+lred in this study, these observations suggest
that cardiac performance improved (rather than deterio-
rated) during treatment with dobutamine
.
Nearly half (7 of 15) of the deaths that occurred in
patients assigned to treatment with dobutamine took place
during the 48 h weekly infusion of the drug (11,12) . This
observation suggests that the drug infusion regimen in itself
contributed importantly to the high mortality seen in treated
patients
. If deaths occurring during the infusion of dobuta-
mine are excluded from the analysis, the mortality in the two
treatment groups is similar (8 [22%] of 37 for dobutamine ; 5
of 23 or 22% for placebo) . in this study, a relatively high
dose (mean dose 8 .1 µg/kg per min) of a potent agent was
administered to patients whose metabolic status and arrhyth-
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mia prevalence were not known before or during the infu-
sion. The study design did not permit physicians to detect or
correct potential metabolic and electrolyte abnormalities or
to treat any electrical complications that might have oc-
curred
. Hence, conclusions regarding the effect of positive
inotropic drugs on the survival of patients with chronic heart
failure are not warranted on the basis of findings of the
intermittent intravenous dobutamine trial,
Effect of phosphudiesterase Inhibitors on survival in heart
failure. The first phosphodiesterase inhibitor to be evaluated
in a controlled clinical trial was amrinone (13). This agent,
when administered to 99 patients with moderate to severe
heart failure for 3 months, appeared to have no effect on
survival when compared with placebo . Unfortunately, we
can draw 'ew conclusions from this study because dose-
relatcd side effects necessitated either the withdrawal ofor a
reduction in the dose of amrinone to subtherapeutic levels in
the majority of patients . The use of low doses of the drug
probably explains the inability of this trial to demonstrate
any benefit of amrinone on symptoms and exercise toler-
ance. Several new phosphudiesterase inhibitors exhibit a
more favorable toxicltherapeatic ratio than does amrinone
and therefore appear more likely to be clinically useful
during long-term therapy .
To date . most of the reported long-term experience with
phosphudiesterase inhibitors has been with milrinone, a
second-generation congener of aminone that is hemody-
namically effective during long-term therapy (1) . Three re-
cently completed trials (referred to as P-706, P-712 and
MI-IA) have evaluated the long-term efficacy and safety of
milrinone in patients with chronic heart failure .
Trial P-706 (14,15) enrolled 230 patients with moderate to
severe symptoms with a mean left ventricular ejection frac-
tion of 0
.23 . After patients were clinically stable on a
regimen of digitalis and diuretics for 4 to 8 weeks, they were
randomly assigned (in a double-blind manner) to one of four
treatment groups for 3 months : diuretics alone (digoxin
withdrawal), diuretics plus digoxin, diuretics plus milrinone
(substitution of milrinone for digoxin) or diuretics plus both
digoxin and mihinone (addition of milrinone to previous
regimen). Crossover from placebo to active drug groups was
not allowed. In patients withdrawn from digoxin, milrinone
produced a significant increase In exercise capacity com-
pared with placebo (14,15) . Twenty-one of the 230 patients
died during the 3 month trial . Multivaricte analysis indicated
that only the pretreatment left ventricular ejection fraction
was a significant predictor of survival in this study . Unfor-
tunately, the randomization process restated in a significant
imbalance in the values for ejection fraction in the four
treatment groups such that more patients with a very low
ejection fraction were randomly assigned to treatment with
milrinone (p < 0
.01). When the survival of patients in this
study was adjusted for this imbalance, there was no signifi-
cant effect of milrinone on mortality, regardless of the
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method of analysis ("intention to treat", p = 0.26 or "actual
treatment", p = 0 .34) .
A second trial (P-712) enrolled 155 patients with moderate
to severe chronic heart failure . After stabilization on treat-
ment with difjtalis and diuretics, patients were randomly
assigned (in a double-blind fashion) to one of three treatment
groups for 3 months : diuretic plus digoxin, diuretic plus
milrinone (substitution of milrinone for digoxin) and diuretic
plus digoxin and milrinone (addition of milrinone to previous
regimen) . In this trial, the randomization process resulted in
a similar distribution of values for left ventricular ejection
fraction among the treatment groups, and thus no adjustment
of survival data was required. As in P-706, no effect of
milrinone on survival was found (p = 0.87) (15)
.
A third trial (MI-1A) enrolled 186 patients with moderate
to severe chronic heart failure who were randomly assigned
to treatment with either milrinone or placebo for 6 months in
addition to their previous therapy with digoxin and diuretics .
As in P-706 and P-712, milrinone had no effect on survival (p
= 0 .75) (15) .
These three controlled trials (reflecting the experience
with milrinone in 571 patients) do not support the thesis that
long-term treatment with positive inotropic drugs adversely
affects survival in chronic heart failure . However, these
findings should not be generalized to other positive isotropic
agents, including other phosphodiesterase inhibitors, he-
cause other drags may differ from milrinone in significant
ways
.
Effects of milrinone on sudden death, myocardial energet-
tes and diastolic relaxation . Do the data for milrinone (2-5)
support any of the theoretical mechanisms by which positive
inotropic agents may adversely affect survival in chronic
heart failure? Does milrinone increase the incidence of
sudden death? Apparently not . In studies P-706 and P-712,
the incidence of sudden death with milrinone (40%) was
similar to that seen in patients who received placebo (45%)
(14,15) . In trial MI-IA, the incidence of sudden death with
milrinone (50%) was no greater than that for placebo (100%)
(I5). These data do not support the thesis that positive
inotropic agents adversely affect the incidence of sudden
death in chronic heart failure .
Does milrinone exert an adverse effect on myocardial
energetics in chronic heart failure? Because myocardial
contractility is an important determinant of myocardial en-
ergy cxpenditure, it is possible that positive inotropic agents
may increase myocardial oxygen consumption and thereby
adversely affect energy stores in the failing heart . The
improvement in pump function that follows milrinone ther-
apy, however, is not associated with an increase in myocar-
dial oxygen demand (16,17), presumably because the periph-
eral vasodilating effects of milrinone act to reduce
myocardial oxygen consumption and thus offset any adverse
effect on myocardial energetics that might be expected to
follow an increase in cardiac contractility .
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Finally, does milrinone adversely affect myocardial re-
laxation (lusitropy) or diastolic filling in chronic heart fail-
ure?
Apparently not
. Both intravenous and oral milrinone
have been shown to improve diastolic function, as evidenced
by a downward displacement of the left ventricular diastolic
pressure-volume relation that follows treatment with this
drug (18,19) . Hence, milrinone appears to exert a favorable
direct lusitropic action, as might be anticipated after the
administration of any agent that acts to increase myocardial
levels of cyclic adenosine monophosphate (AMP) .
Effects of mllrinone on survival In experimental heart
failure. The rat coronary artery ligation model of left ven-
tricular dysfunction has been used to demonstrate that both
captopril (20) and enalapril (21) improve survival in experi-
mentally induced chronic heart failure . Recently, Sweet et
al . (21), using the same model, demonstrated that milrinone
increased the median survival time of rats with myocardial
infarction by 49% ; the magnitude of this benefit exceeded
that seen with enataprl in the same model . Although such
data cannot be extrapolated to the clinical setting, they do
not support the view that positive inotropic agents adversely
affect survival and they raise the possibility fiat milrinone
could affect survival in a beneficial way.
Conclusions. Controlled data with milrinone do not dem-
onstrate an adverse effect of long-term treatment with this
drug on the survival of patients with chronic heart failure,
and they fail to support the importance of any of the
theorized mechanisms by which positive inotropic agents
could potentially adversely affect survival . Although these
data are encouraging, final conclusions regarding the effects
of positive inotropic agents on patient survival will require
larger studies conducted for longer periods affirm . Because
the extent to which the safety profile of milrinone is favor-
ably influenced by the drag's peripheral vasodilator actions
is unknown, these data do not allow conclusions regarding
the safety of pure positive inotropic agents. Preliminary
observations with the intermittent use of intravenous debu-
tamine in chronic heart failure do not allow conclusions
regarding the long-term effects of positive inotropic therapy
but raise concerns regarding the safety of the ambulatory
dohutamine infusion method
.
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